Outcomes of patients with acute coronary syndrome according to COVID-19 vaccination status.
- Resource Type
- Academic Journal
- Authors
- Hilu R; Cardiology Department, Meir Medical Center, Kfar-Saba and Sackler Faculty of Medicine, Tel-Aviv University.; Abu Ghosh Z; Hadassah Hebrew University Medical Center, Jerusalem.; Leibowitz D; Hadassah Hebrew University Medical Center, Jerusalem.; Arow Z; Cardiology Department, Meir Medical Center, Kfar-Saba and Sackler Faculty of Medicine, Tel-Aviv University.; Ovdat T; The Israeli Center for Cardiovascular Research, Sheba Medical Center, Ramat Gan.; Or T; Cardiology Department, Galilee Medical Center, Nahariya and Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.; Pereg D; Cardiology Department, Meir Medical Center, Kfar-Saba and Sackler Faculty of Medicine, Tel-Aviv University.; Alcalai R; Hadassah Hebrew University Medical Center, Jerusalem.
- Source
- Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9011445 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-5830 (Electronic) Linking ISSN: 09546928 NLM ISO Abbreviation: Coron Artery Dis Subsets: MEDLINE
- Subject
- Language
- English
Background: COVID-19 vaccination has been associated with reduced risk of acute coronary syndrome (ACS); however, several studies have reported cardiovascular complications following vaccination. We aimed to investigate the effect of COVID-19 vaccination status on the treatment and outcome of ACS patients.
Methods: The study was based on the 2021 Acute Coronary Syndrome Israeli Survey. Patients were stratified into two groups according to COVID-19 vaccination status, vaccinated compared to unvaccinated. Patients who had received at least 2 vaccination doses up to 1 week prior to ACS hospitalization were considered vaccinated. The primary endpoint was 1-year all-cause mortality.
Results: A total of 1261 patients with ACS were included, of whom 990 (78.5%) were vaccinated. Vaccinated patients were older and less frequently smokers. There were no significant differences in coronary reperfusion rates and treatment with guideline-based medical therapy during hospital stay and at discharge. The primary endpoint of 1-year all-cause mortality occurred in 38 (3.8%) and 14 (5.2%) patients in the vaccinated and unvaccinated groups respectively (P = 0.42). 30-day MACE occurred in 94 (9.5%) in the vaccinated patients compared to 31 (11.5%) in the unvaccinated group (P = 0.39). These results remained similar following adjustment for confounders.
Conclusion: There was no association between COVID-19 vaccination status and the outcomes of patients with ACS. Our findings provide support for the cardiovascular safety of COVID-19 mRNA vaccines in patients at high cardiovascular risk.
(Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)